Concepedia

Ramakrishna Edupuganti

RE

16

Publications

612

Citations

15

H-Index

2012

Active since

Affiliations

The University of Texas at Austin(Current)

The University of Texas MD Anderson Cancer Center

Minia University

Harvard University

Temple University

Ramakrishna Edupuganti is an author at The University of Texas at Austin specializing in medicine, pharmacology, and drug discovery.

ORCID

Top concepts

Publications per year

2012–2023

16

Publications

16

c-Jun N-terminal kinase promotes stem cell phenotype in triple-negative breast cancer through upregulation of Notch1 via activation of c-Jun

Xuemei Xie, Tamer S. Kaoud, Ramakrishna Edupuganti et al. · Oncogene · 2016 · 99 citations · Full text

, , +11

Definition of a Novel Feed-Forward Mechanism for Glycolysis-HIF1α Signaling in Hypoxic Tumors Highlights Aldolase A as a Therapeutic Target

Geoffrey Grandjean, Petrus R. de Jong, Brian P. James et al. · Cancer Research · 2016 · 78 citations

Synthesis and biological evaluation of pyrido[2,3-d]pyrimidine-2,4-dione derivatives as eEF-2K inhibitors

Ramakrishna Edupuganti, Qiantao Wang, Clint D.J. Tavares et al. · Bioorganic & Medicinal Chemistry · 2014 · 76 citations · Full text

, , +8

Serotonin Analogues as Inhibitors of Breast Cancer Cell Growth

Jiney Jose, Clint D.J. Tavares, Nancy D. Ebelt et al. · ACS Medicinal Chemistry Letters · 2017 · 50 citations

A c-Jun N-terminal kinase inhibitor, JNK-IN-8, sensitizes triple negative breast cancer cells to lapatinib

Nancy D. Ebelt, Tamer S. Kaoud, Ramakrishna Edupuganti et al. · Oncotarget · 2017 · 40 citations · Full text

Rows per page

1–5 of 16